Analyst firms · Morgan Stanley · EXEL

Morgan Stanley EXEL price target and rating history

Exelixis Inc. (EXEL) · Health Care

Morgan Stanley rates Exelixis Inc. (EXEL) Equal-Weight with a $48 price target, as of its latest action on Jan 8, 2026. It has published 3 rating actions on EXEL since July 2023, including 1 upgrade and 1 downgrade. Across 5 firms with a EXEL price target in the last 12 months, the median target is $52. Morgan Stanley's $48 is 8% below that.

Current rating
Equal-Weight
Price target
$48
Median target, all firms
$52
Actions on EXEL
3

Morgan Stanley price target on EXEL

$48$35$21202420252026
Morgan Stanley price target on EXEL, each point a stated target, July 2023 to January 2026.

Every Morgan Stanley rating on EXEL

How other firms rate EXEL

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
BMO Capital MarketsMarket Perform$54Aug 19, 2026
Leerink PartnersMarket Perform$52Aug 6, 2026
Truist SecuritiesHold$54Jun 25, 2026
Morgan StanleyEqual-Weight$48Jan 8, 2026
BofA SecuritiesUnderperform$41Jan 5, 2026
Wolfe ResearchPeer PerformNov 18, 2025

Questions about Morgan Stanley and EXEL

What is Morgan Stanley's price target for EXEL?
Morgan Stanley's latest stated price target for Exelixis Inc. (EXEL) is $48, from its action on Jan 8, 2026.
What is Morgan Stanley's rating on EXEL?
Morgan Stanley rates EXEL Equal-Weight, a neutral rating, as of Jan 8, 2026.
When did Morgan Stanley last change its view on EXEL?
On Jan 8, 2026, Morgan Stanley downgrades to Equal-Weight from Overweight, price target $48.
How does Morgan Stanley's EXEL target compare with other analysts?
Across 5 firms with a EXEL price target in the last 12 months, the median target is $52. Morgan Stanley's $48 is 8% below that.

More EXEL rating histories

All Morgan Stanley ratingsEXEL news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.